biOasis Presents Results From It’s BT2111 Program at International Cancer Research Conference

**biOasis and collaborators from Alexandria University, Egypt; Texas Tech University HSC, Amarillo, Texas and; the West Virginia University HSC, School of Pharmacy, Morgantown, WV; Presents Progress in Developing a Novel Therapy to Treat Brain Metastases of Breast Cancer**

**VANCOUVER, BRITISH COLUMBIA, April 3, 2014.** biOasis Technologies Inc. (TSXV: BTI; OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, will present results from it’s BT2111 program at the 105th Annual Meeting of the American Academy of Cancer Research (AACR) being held April 5th to 9th, 2014, in San Diego, California.

Details of the presentations are as follows:

**Presentation 642. Transcend, a protein vector for brain delivery, allows trastuzumab to reach the brain at effective concentration after incorporation to form BT2111**

**Session:** Immune Mechanisms Invoked by Radiation, Chemotherapy, or Targeted Therapy  
**Session Time:** Apr 6, 1:00 - 5:00 PM

**Presentation 2653. Anti-cancer antibody trastuzumab-melanotransferrin conjugate (BT2111) for the treatment of metastatic HER2+ breast cancer tumors in the brain: An in vivo study**

**Session:** New Antibodies and Antibody Drug Conjugates  
**Session Time:** Apr 7, 1:00 - 5:00 PM

**Presentation 2905. The activity of a new class of biologics: trastuzumab conjugates designed to treat brain metastases of HER2+ breast cancers**

**Session:** Prophylactic and Therapeutic Immune-based Therapies  
**Session Time:** Apr 7, 1:00 - 5:00 PM

**About BT2111**

BT2111 is a hybrid drug candidate consisting of a biOasis' Transcend delivery vector linked to trastuzumab, a humanized monoclonal antibody used clinically in the treatment of HER2+ breast cancer. It is reported that up to 30% of HER2+ breast cancer patients develop brain metastasis for which therapeutic options are limited. Because of its ability to cross the blood-brain barrier, biOasis is developing BT2111 as a potential treatment for brain metastases of HER2+ breast cancer.

**About the 105th AACR Annual Meeting**

The 105th Annual Meeting of the American Association for Cancer Research, the premier annual cancer research event where the latest and most exciting basic, translational, and clinical discoveries are presented, will be held April 5-9, 2014, in San Diego, California. The theme for this year’s meeting, “Harnessing Breakthroughs – Targeting Cures,” reflects the fact that the translation of basic science into clinical advances for the benefit of cancer patients is occurring at an increasing pace and more seamlessly than ever before. Approximately 18,000 researchers, patient advocates, and other professionals in the cancer field from around the world are scheduled to be in attendance. The 2014 AACR meeting provides a unique opportunity for members of the worldwide cancer research community to learn about cutting-edge advances,
obtain feedback on their own research, and make connections that will foster future collaborations. For more information on the 105th AACR Annual Meeting please visit:

http://www.aacr.org/home/scientists/meetings--workshops/aacr-annual-meeting-2014.aspx

**About Transcend**

Transcend offers the creation of a new class of drugs that can cross the blood-brain barrier to address unmet medical needs in the treatment of brain metastatic cancer and other brain disorders, such as neurodegeneration and metabolic disease. The blood-brain barrier represents the single greatest challenge in treating diseases and other disorders within the brain. Diseases such as cancer are readily treated in many areas of the body, but drugs designed to treat cancer simply cannot penetrate the blood-brain barrier.

Over the past five years, biOasis has developed a unique and novel blood-brain barrier vector called Transcend. Trials in animal models have shown that Transcend can deliver Herceptin®, a chemotherapeutic used to treat HER2-positive breast cancer, in sufficient quantity to the brain to significantly reduce the number of HER2-positive metastatic brain tumors. Further, after only four treatments, the remaining tumor masses were reduced in size by an average of 58%.

Also in animal models, the company has demonstrated that the Transcend vector could deliver a 4-to-8-fold increase of a variety of different therapeutic biologics across the blood-brain-tumor barrier versus the compounds on their own.

The ability to more effectively permeate both the blood-brain and the blood-tumor barrier opens the door for the creation of new drugs designed to treat a wide variety of neurological diseases and disorders. Additionally, Transcend offers the potential to take existing clinically approved drugs that are near their end of patent life and extend them.

**About biOasis**

biOasis Technologies Inc. is a biopharmaceutical company headquartered in Richmond, BC, Canada. Based on Transcend, biOasis’ proprietary brain delivery platform, the company is focused on creating new drugs that can cross the blood-brain barrier to address unmet medical needs in the treatment of brain disorders such as neurodegeneration, metastatic cancer and metabolic diseases. biOasis trades on the OTCQX under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI”. For more information about the company please visit www.bioasis.ca.

**Forward Looking Statements**

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and
uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors
Rob Hutchison Chairman & CEO

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”

Company Contact:
Rob Hutchison, Chairman & CEO
biOasis Technologies Inc.
Tel 778-383-3280
rob@bioasis.ca

Investor Relations Contact:
Ron Both, Senior Managing Director
Liolios Group, Inc.
Tel 949-574-3860
BTI@liolios.com